Phase 2 Colorectal Cancer Trial, Recruiting NCT06279351 Sponsor: Xinqiao Hospital of Chongqing Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT06279351
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with stage IV colorectal cancer (on the left side of the colon) that cannot be removed by surgery, confirmed by lab testing, and your cancer has specific genetic features called "RAS and BRAF wild-type"
  • You are in generally good physical health and able to carry out daily activities (your doctor will assess this using a standard scale)
  • Your doctor expects you to live for more than 3 months
  • You are between 18 and 75 years old
  • You have not had chemotherapy treatment before for this cancer
  • You have not previously been treated with a drug called cetuximab
  • Your liver, kidney, and bone marrow are functioning at a reasonably normal level
  • If you have had any previous chemotherapy or targeted therapy, it was completed more than 4 weeks ago
  • You are willing to take part, are able to follow the study requirements, and are happy to sign a consent form

Who may not be able to join:

  • You have serious problems with a major organ such as your heart, liver, or kidneys
  • You have been diagnosed with another type of cancer
  • You are pregnant or breastfeeding (women who could become pregnant will need to take a pregnancy test)
  • You currently have an active infection, either short-term or ongoing
  • You have a known history of significant drug allergies or are generally prone to allergic reactions
  • You are already taking part in another clinical trial
  • Your doctor decides there is another reason why joining this study would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: rui kong, doctor, Chongqing Medical University

Phone: 023-68774490

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xinqiao Hospital of Chongqing
Registry
ClinicalTrials.gov
Start date
11 August 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ETS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov